BioSpace News Archive

Bio-Techne Corporation announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation Award.

Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that management will participate in virtual fireside chats at the following investor conferences

Labcorp, a leading global life sciences company, announced the appointment of Kathryn Wengel, current Executive Vice President and Chief Global Supply Chain Officer at Johnson & Johnson, as an independent member of Labcorp’s Board of Directors, effective immediately.

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today announced that it has entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”), a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH).

NeuPath Health Inc. (TSXV:NPTH) (formerly Klinik Health Ventures Corp.) (“NeuPath” or the “Company”), Canada’s largest provider of chronic pain management services, today announced its financial and operating results for the three months and year ended December 31, 2020.

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2020 annual results which ended on Dec. 31, 2020.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced an interview with Vu Truong, Ph.D., Chief Executive Officer will air on The RedChip Money Report®

Sexton Biotechnologies, in partnership with Hitech Health and Med Institute, is working towards continued innovations in flexible automation

As more and more schools work to support in-person learning environments, communities across the country have turned to COVID-19 testing programs to monitor the virus. Even as teachers and guardians become eligible for and receive effective and safe vaccines, clinical vaccine trials for individuals under 16 are just beginning, and efforts to track and mitigate viral spread remain critical.

For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is often recommended for first-line treatment. A new study in JCO Precision Oncology shows the Guardant360® liquid biopsy test provides an early indication of treatment response to pembrolizumab-based immunotherapy by detecting molecular response or changes in circulating tumor DNA (ctDNA) levels early on